If you can spare a few minutes, please help us improve our website by completing this survey.
The MIT Center for Precision Cancer Medicine (CPCM) is devoted to translational research to help the subset of patients who do not respond well to traditional therapies. By focusing on the use of drug combinations, CPCM investigators believe it is possible to significantly alter patient outcomes by determining the right combination of therapies for the right patients. In addition, the Center will concentrate efforts on innovative ways to give drugs, be it in time-staggered dosages, or formulations that target the therapy directly to the tumor. The four focus areas of the CPCM are:
By galvanizing the MIT cancer research community, clinical investigators, and industry, the Center will help to revolutionize cancer diagnosis, treatment, and monitoring.
The CPCM will invest in collaborative research efforts; offer a robust training ground for young engineers and scientists and convene scientific symposia and events.
CPCM investigators include:
Michael Yaffe, MD, PhD, Director
Michael Hemann, PhD
Angela Koehler, PhD
Scott Manalis, PhD
Matthew Vander Heiden, MD, PhD
Forest White, PhD